肺腺癌EGFR突变患者一线化疗与靶向治疗生存分析

目的 对肺腺癌EGFR19号外显子缺失和EGFR21号外显子突变患者一线化疗和靶向治疗进行生存分析.方法 回顾性收集番禺中心医院就诊的101例肺腺癌患者资料,筛选出45例已做EGFR检测的患者,分析EGFR基因突变与临床各病理参数之间的关系.在45例EGFR基因突变患者中,筛选出19例19号外显子缺失和14例21号外显子突变患者,分别分析其一线化疗和靶向治疗生存状况.结果 19号外显子缺失患者的中位总生存期(OS)为11.2个月,较21号外显子突变者的10.3个月长,差异具有统计学意义(P<0.05);19号外显子缺失患者靶向治疗的OS为12.2个月,较一线化疗的10.1个月长,差异具有统计学意义(P<0.05);21外显子突变患者靶向治疗的OS为11.5个月,较一线化疗的8.3个月时间长,差异具有统计学意义(P<0.05).结论 在肺腺癌EGFR19号外显子缺失和EGFR21外显子突变患者中,靶向治疗总生存时间较一线化疗的总生存时间长.

Survival analysis on patients of lung adenocarcinoma with mutated EGFR undergoing first-line chemotherapy and targeted therapy

Objective To analyze the survival of lung adenocarcinoma patients with exon 19 deletion and exon 21 mutation in epidermal growth factor receptor (EGFR) gene who were treated with first-line chemotherapy and target-ed therapy, respectively. Methods The clinical data of 101 lung adenocarcinoma patients from Guangzhou Panyu Cen-tral Hospital were collected, and 45 patients which underwent EGFR testing were selected and enrolled to analyze the re-lationship between the mutations of EGFR gene and clinicopathologic features. Among the 33 patients with mutations in EGFR gene, there were 19 patients with exon 19 deletion and 14 patients with exon 21 mutation. The survival status of the patients were analyzed between first-line chemotherapy and targeted therapy. Results The median overall survival (OS) of patients with exon 19 mutation was significantly longer than that of the patients with exon 21 mutation (11.2 months vs 10.3 months, P<0.05). The OS of patients with exon 19 mutation undergoing targeted therapy was significantly longer than that of the patients undergoing first-line chemotherapy (12.2 months vs 10.1 months, P<0.05). The OS of patients with exon 21 mutation undergoing targeted therapy was significantly longer than that of the patients undergoing first-line chemothera-py (11.5 months vs 8.3 months, P<0.05). Conclusion For the lung adenocarcinoma patients with mutations in the exons 19, 21 of EGFR gene, the overall survival of targeted therapy is longer than that of first-line chemotherapy.